Changes Within the Thyroid Axis During the Course of Critical Illness

Endocrinology and Metabolism Clinics of North America

Volumn 35, Issue 4, 2006, Pages 807-821

  Mebis, Liese ^a   Debaveye, Yves ^a   Visser, Theo J ^b   Van den Berghe, Greet ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; DEIODINASE D1; DEIODINASE D2; DEIODINASE D3; GROWTH HORMONE SECRETAGOGUE; IODIDE PEROXIDASE; LIOTHYRONINE; MELANOCORTIN; PROTIRELIN; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

BINDING KINETICS; CRITICAL ILLNESS; DEIODINATION; DISEASE COURSE; ENZYME ACTIVITY; HORMONE BINDING; HORMONE TRANSPORT; HUMAN; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRESS; SULFATION; THYROID DISEASE; THYROID FUNCTION; THYROID HORMONE METABOLISM; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; THYROXINE BLOOD LEVEL; TISSUE LEVEL;

CRITICAL ILLNESS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTENSIVE CARE; PITUITARY-ADRENAL SYSTEM; THYROID GLAND; THYROID HORMONES;

EID: 33751236464     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.09.009     Document Type: Review

References (85)

1. Larsen P.R., Davies T.F., and Hay I.D. The thyroid gland. In: Wilson J.D., Foster D.W., Kronenberg H.M., et al. (Eds). Williams textbook of endocrinology. 9th edition (1998), WB Saunders, Philadelphia 389-515
2. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol Rev 81 (2001) 1097-1142
3. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23 (2002) 38-89
4. Docter R., Krenning E.P., de Jong M., et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 39 (1993) 499-518
5. Rothwell P.M., and Lawler P.G. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 23 (1995) 78-83
6. Wartofsky L., and Burman K.D. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev 3 (1982) 164-217
7. Michalaki M., Vagenakis A.G., Makri M., et al. Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 86 (2001) 4198-4205
8. Van den Berghe G., de Zegher F., Veldhuis J.D., et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 47 (1997) 599-612
9. Leonard J.L., and Koehrle J. Intracellular pathways of iodothyronine metabolism (2000), Lippincott Williams & Wilkins, Philadelphia
10. Bianco A.C., and Larsen P.R. Cellular and structural biology of the deiodinases. Thyroid 15 (2005) 777-786
11. Luiza Maia A., Kim B.W., Huang S.A., et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115 (2005) 2524-2533
12. Carter J.N., Eastmen C.J., Corcoran J.M., et al. Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. Clin Endocrinol (Oxf) 5 (1976) 587-594
13. Chopra I.J., Chopra U., Smith S.R., et al. Reciprocal changes in serum concentrations of 3,3′,5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab 41 (1975) 1043-1049
14. Peeters R.P., Wouters P.J., Kaptein E., et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88 (2003) 3202-3211
15. Debaveye Y., Ellger B., Mebis L., et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology 146 (2005) 5604-5611
16. Weekers F., Van Herck E., Coopmans W., et al. A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143 (2002) 764-774
17. Boelen A., Kwakkel J., Thijssen-Timmer D.C., et al. Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol 182 (2004) 315-323
18. Boelen A., Kwakkel J., Alkemade A., et al. Induction of type 3 deiodinase activity in inflammatory cells of mice with chronic local inflammation. Endocrinology 146 (2005) 5128-5134
19. O'Mara B.A., Dittrich W., Lauterio T.J., et al. Pretranslational regulation of type I 5′-deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology 133 (1993) 1715-1723
20. Crantz F.R., Silva J.E., and Larsen P.R. An analysis of the sources and quantity of 3,5,3′-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology 110 (1982) 367-375
21. Salvatore D., Bartha T., Harney J.W., et al. Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137 (1996) 3308-3315
22. Gereben B., Goncalves C., Harney J.W., et al. Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol 14 (2000) 1697-1708
23. Zimmerman D. Fetal and neonatal hyperthyroidism. Thyroid 9 (1999) 727-733
24. Richard K., Hume R., Kaptein E., et al. Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab 83 (1998) 2868-2874
25. Huang S.A., Tu H.M., Harney J.W., et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343 (2000) 185-189
26. de Jong M., Visser T.J., Bernard B.F., et al. Transport and metabolism of iodothyronines in cultured human hepatocytes. J Clin Endocrinol Metab 77 (1993) 139-143
27. Hennemann G., Krenning E.P., Polhuys M., et al. Carrier-mediated transport of thyroid hormone into rat hepatocytes is rate-limiting in total cellular uptake and metabolism. Endocrinology 119 (1986) 1870-1872
28. Hennemann G., Everts M.E., de Jong M., et al. The significance of plasma membrane transport in the bioavailability of thyroid hormone. Clin Endocrinol (Oxf) 48 (1998) 1-8
29. Lim C.F., Docter R., Visser T.J., et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab 76 (1993) 1165-1172
30. Lim C.F., Docter R., Krenning E.P., et al. Transport of thyroxine into cultured hepatocytes: effects of mild non-thyroidal illness and calorie restriction in obese subjects. Clin Endocrinol (Oxf) 40 (1994) 79-85
31. Sarne D.H., and Refetoff S. Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J Clin Endocrinol Metab 61 (1985) 1046-1052
32. Vos R.A., de Jong M., Bernard B.F., et al. Impaired thyroxine and 3,5,3′-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metab 80 (1995) 2364-2370
33. Friesema E.C., Ganguly S., Abdalla A., et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 278 (2003) 40128-40135
34. Peeters R.P., van der Geyten S., Wouters P.J., et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab 90 (2005) 6498-6507
35. Arem R., Wiener G.J., Kaplan S.G., et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism 42 (1993) 1102-1108
36. Timmer DC, Peeters RP, Wouters P, et al. Thyroid hormone receptor alpha splice variants in livers of critically ill patients. Thyroid, in press.
37. Carr F.E., Seelig S., Mariash C.N., et al. Starvation and hypothyroidism exert an overlapping influence on rat hepatic messenger RNA activity profiles. J Clin Invest 72 (1983) 154-163
38. Thompson Jr. P., Burman K.D., Lukes Y.G., et al. Uremia decreases nuclear 3,5,3′-triiodothyronine receptors in rats. Endocrinology 107 (1980) 1081-1084
39. Visser T.J., Kaptein E., Glatt H., et al. Characterization of thyroid hormone sulfotransferases. Chem Biol Interact 109 (1998) 279-291
40. Chopra I.J., Wu S.Y., Teco G.N., et al. A radioimmunoassay for measurement of 3,5,3′-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab 75 (1992) 189-194
41. Eelkman Rooda S.J., Kaptein E., and Visser T.J. Serum triiodothyronine sulfate in man measured by radioimmunoassay. J Clin Endocrinol Metab 69 (1989) 552-556
42. Peeters R.P., Kester M.H.A., Wouters P.J., et al. Increased T4S levels in critically ill patients due to a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab 90 (2005) 6460-6465
43. Afandi B., Vera R., Schussler G.C., et al. Concordant decreases of thyroxine and thyroxine binding protein concentrations during sepsis. Metabolism 49 (2000) 753-754
44. Afandi B., Schussler G.C., Arafeh A.H., et al. Selective consumption of thyroxine-binding globulin during cardiac bypass surgery. Metabolism 49 (2000) 270-274
45. den Brinker M., Joosten K.F., Visser T.J., et al. Euthyroid sick syndrome in meningococcal sepsis: the impact of peripheral thyroid hormone metabolism and binding proteins. J Clin Endocrinol Metab 90 (2005) 5613-5620
46. Chopra I.J., Huang T.S., Beredo A., et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3′-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 60 (1985) 666-672
47. Kaptein E.M. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 17 (1996) 45-63
48. Brent G.A., and Hershman J.M. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 63 (1986) 1-8
49. Wellby M.L., Kennedy J.A., Barreau P.B., et al. Endocrine and cytokine changes during elective surgery. J Clin Pathol 47 (1994) 1049-1051
50. Van den Berghe G., de Zegher F., Baxter R.C., et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83 (1998) 309-319
51. Mesotten D., and Van den B.G. Changes within the GH/IGF-I/IGFBP axis in critical illness. Crit Care Clin 22 (2006) 17-28 [v]
52. Fliers E., Guldenaar S.E., Wiersinga W.M., et al. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 82 (1997) 4032-4036
53. Bacci V., Schussler G.C., and Kaplan T.B. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 54 (1982) 1229-1235
54. Hamblin P.S., Dyer S.A., Mohr V.S., et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 62 (1986) 717-722
55. Peeters R.P., Wouters P.J., van Toor H., et al. Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 90 (2005) 4559-4565
56. Boelen A., Platvoet-ter Schiphorst M.C., Bakker O., et al. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. J Endocrinol 146 (1995) 475-483
57. van der Poll T., Romijn J.A., Wiersinga W.M., et al. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 71 (1990) 1567-1572
58. van der Poll T., Van Zee K.J., Endert E., et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 80 (1995) 1341-1346
59. Boelen A., Platvoet-ter Schiphorst M.C., and Wiersinga W.M. Immunoneutralization of interleukin-1, tumor necrosis factor, interleukin-6 or interferon does not prevent the LPS-induced sick euthyroid syndrome in mice. J Endocrinol 153 (1997) 115-122
60. Damas P., Reuter A., Gysen P., et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17 (1989) 975-978
61. Boelen A., Platvoet-ter Schiphorst M.C., and Wiersinga W.M. Association between serum interleukin-6 and serum 3,5,3′-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77 (1993) 1695-1699
62. Boelen A., Schiphorst M.C., and Wiersinga W.M. Relationship between serum 3,5,3′-triiodothyronine and serum interleukin-8, interleukin-10 or interferon gamma in patients with nonthyroidal illness. J Endocrinol Invest 19 (1996) 480-483
63. Van den Berghe G., de Zegher F., and Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf) 41 (1994) 731-737
64. Faglia G., Ferrari C., Beck-Peccoz P., et al. Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects. Horm Metab Res 5 (1973) 289-292
65. Diano S., Naftolin F., Goglia F., et al. Fasting-induced increase in type II iodothyronine deiodinase activity and messenger ribonucleic acid levels is not reversed by thyroxine in the rat hypothalamus. Endocrinology 139 (1998) 2879-2884
66. Fekete C., Sarkar S., Christoffolete M.A., et al. Bacterial lipopolysaccharide (LPS)-induced type 2 iodothyronine deiodinase (D2) activation in the mediobasal hypothalamus (MBH) is independent of the LPS-induced fall in serum thyroid hormone levels. Brain Res 1056 (2005) 97-99
67. Alkemade A., Friesema E.C., Unmehopa U.A., et al. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab 90 (2005) 4322-4334
68. Lechan R.M., and Fekete C. Role of melanocortin signaling in the regulation of the hypothalamic-pituitary-thyroid (HPT) axis. Peptides 27 (2006) 310-325
69. Ahima R.S., Saper C.B., Flier J.S., et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 21 (2000) 263-307
70. Sergeyev V., Broberger C., and Hokfelt T. Effect of LPS administration on the expression of POMC, NPY, galanin, CART and MCH mRNAs in the rat hypothalamus. Brain Res Mol Brain Res 90 (2001) 93-100
71. Fliers E., Unmehopa U.A., Manniesing S., et al. Decreased neuropeptide Y (NPY) expression in the infundibular nucleus of patients with nonthyroidal illness. Peptides 22 (2001) 459-465
72. Pizzagalli F., Hagenbuch B., Stieger B., et al. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16 (2002) 2283-2296
73. Clerget-Froidevaux M.S., Seugnet I., and Demeneix B.A. Thyroid status co-regulates thyroid hormone receptor and co-modulator genes specifically in the hypothalamus. FEBS Lett 569 (2004) 341-345
74. Van den Berghe G., de Zegher F., and Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83 (1998) 1827-1834
75. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol/European Federation Of Endocrine Societies 143 (2000) 1-13
76. Van den Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 23 (2002) 370-391
77. Gardner D.F., Kaplan M.M., Stanley C.A., et al. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 300 (1979) 579-584
78. Utiger R.D. Decreased extrathyroidal triiodothyronine production in nonthyroidal illness: benefit or harm?. Am J Med 69 (1980) 807-810
79. Van den Berghe G., Wouters P., Weekers F., et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84 (1999) 1311-1323
80. Van den Berghe G., Baxter R.C., Weekers F., et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56 (2002) 655-669
81. Vaughan G.M., Mason Jr. A.D., McManus W.F., et al. Alterations of mental status and thyroid hormones after thermal injury. J Clin Endocrinol Metab 60 (1985) 1221-1225
82. Becker R.A., Vaughan G.M., Ziegler M.G., et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 10 (1982) 870-875
83. Bettendorf M., Schmidt K.G., Grulich-Henn J., et al. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study. Lancet 356 (2000) 529-534
84. Debaveye Y., and Van den Berghe G. Is there still a place for dopamine in the modern intensive care unit?. Anesth Analg 98 (2004) 461-468
85. Van den Berghe G., de Zegher F., Vlasselaers D., et al. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med 24 (1996) 590-595